Evidence map›Paper›PMID 42350924›Full record

ArticleAlimentary pharmacology & therapeutics2026

Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design.

Søren S Olesen, Niels Henrik Bruun, Line Davidsen, Srdan Novovic, Stig B Laursen, Enrique de-Madaria, Dhiraj Yadav, Asbjørn M Drewes

Abstract read
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Editorial: Dissecting the Natural History of Recurrent Pancreatitis.Alimentary pharmacology & therapeutics · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Søren S OlesenCentre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.ORCID https://orcid.org/0000-0003-3916-3168
Niels Henrik BruunResearch Data and Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
Line DavidsenCentre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.ORCID https://orcid.org/0000-0002-1120-8144
Srdan NovovicPancreatitis Centre East, Gastro Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Stig B LaursenDepartment of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
Enrique de-MadariaDepartment of Gastroenterology, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain.ORCID https://orcid.org/0000-0002-2412-9541
Dhiraj YadavDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Asbjørn M DrewesCentre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.ORCID https://orcid.org/0000-0001-7465-964X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with acute pancreatitis (AP) often experience recurrent acute pancreatitis (RAP), increasing the risk of chronic pancreatitis (CP) and long-term complications. Progression along the AP-RAP-CP spectrum has been explored in epidemiological studies, but available data provide limited insight into recurrence dynamics within RAP itself. This information is crucial for the design of studies aiming to prevent RAP recurrence and disease progression.

methodsIn this nationwide cohort study, we included 45,338 Danish adults hospitalised with an incident episode of AP between January 1, 2000, and December 31, 2022, identified through national health registries. RAP was defined as recurrent hospitalisations for AP separated by ≥ 90 days. Competing risk models with pseudo-observations estimated cumulative incidence functions for RAP recurrence stratified by the number of prior AP episodes. Inter-episode intervals were estimated using Weibull models.

resultsDuring a median follow-up of 4.5 years, 6894 patients developed RAP, corresponding to a 15.2% risk (95% confidence interval, 14.9%-15.5%). The RAP recurrence risk increased with accumulating episodes. The 12-month cumulative incidence of RAP recurrence rose from 17% after one RAP episode to 46% after five episodes. Most recurrences occurred within 12 months, and inter-episode intervals shortened with increasing episode number. Weibull models demonstrated a wear-out pattern, with shape parameters increasing progressively across successive RAP episodes, indicating accelerating recurrence risk over time.

conclusionsRAP follows an accelerating course characterised by increasing recurrence risk. Risk-enriched trial designs targeting patients with more prior episodes may improve the feasibility and statistical efficiency of future interventional studies.

Indexed as

PancreatitisAcute DiseaseAdultAgedCohort StudiesDenmarkDisease ProgressionFemaleHospitalizationHumansIncidenceMaleMiddle AgedPancreatitis, ChronicRecurrenceRisk Factors

Identifiers

PMID42350924
PMCPMC13559513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.